08:00 , Feb 1, 2010 |  BioCentury  |  Finance

Genzyme's new incentives

In another of several recent moves to appease its restive shareholder base, last week Genzyme Corp. (NASDAQ:GENZ) adopted a new executive incentive plan and gave more power to its lead independent director. Annual incentives for...
00:28 , Jul 16, 2005 |  BC Extra  |  Financial News

Peptimmune raises $20.4 million

Peptimmune (Cambridge, Mass.) raised $20.4 million in a series C round. New investors Itochu and Silicon Valley Bank Capital joined existing investors New Enterprise Associates; MPM Capital; Prism Venture Partners; Vanguard Ventures; Hunt Ventures; and...
08:00 , Mar 15, 2004 |  BioCentury  |  Finance

'A' for effort

'A' for effort Company Raised Date Focus Country Investors Pedigree Biovitrum $85.0 8/1/01 Metabolic Sweden MPM Capital; Nordic Capital; Karolinska Investment Fund; ABN AMRO; Carnegie Asset Management; H&B Capital; Next Gear Spun out of Pharmacia...
08:00 , Jan 12, 2004 |  BC Extra  |  Financial News

Hydra raises $18.9 million

Regenerative medicine company Hydra (Cambridge, Mass.) raised $18.9 million in a series B round led by Lilly BioVentures. Other investors included BioVentures Investors; Polaris; Abingworth; New Enterprise Associates; Advanced Technology Ventures; Abbott (ABT); and Boston...
08:00 , Mar 17, 2003 |  BioCentury  |  Finance

Ebb & Flow

Last Friday was the third anniversary of the popping of the genomics bubble, and biotech valuations continue to drift down. Although the drop is no longer precipitous, the BioCentury 100 index is testing whether it...
08:00 , Mar 12, 2003 |  BC Extra  |  Financial News

Peptimmune raises $41.2 million

Autoimmune company Peptimmune (Cambridge, Mass.) raised $41.2 million in a series A round co-led by New Enterprise Associates and MPM Capital. Other investors included Prism Venture Partners; Vanguard Ventures; Hunt Ventures; and Boston Medical Investors....
07:00 , Jul 29, 2002 |  BC Week In Review  |  Company News

Hydra board of directors update

Hydra Biosciences Inc. , Cambridge, Mass.   Business: Biomaterial/Skin/Wound   Appointed: Robert Carpenter, president of Boston Medical Investors, as chairman; Christoph Westphal, general partner at Polaris Ventures Partners; and Jonathan MacQuitty, director at Abingworth  ...
07:00 , May 4, 1998 |  BC Week In Review  |  Company News

Aquila board of directors update

Aquila Biopharmaceuticals Inc. (AQLA), Worcester, Mass.   Business: Infectious diseases, Autoimmune/Inflammation, Cancer   Appointed: Robert Carpenter, president of Boston Medical Investors Inc. and chairman of GelTex Pharmaceuticals Inc.  ...
07:00 , Aug 4, 1997 |  BioCentury  |  Politics, Policy & Law

No profound difference for biotech

The Capital Gains Tax The budget deal brokered between Congress and the White House promises long-sought relief on capital gains, but will provide only a marginal benefit to the biotech sector, according to initial reactions...
08:00 , Jan 15, 1996 |  BioCentury  |  Strategy

Baxter's busy alumni network

In biotech, it pays to be a Baxter alumnus. In August of 1994, Procept Inc. began thinking about acquiring vaccine technology based on a novel discovery in the area of antigen presentation, but the company...